---
schema_version: "secwatch.filing_event.v1"
accession: "0001477932-26-001016"
form_type: "8-K"
ticker: "TGNT"
cik: "0000846377"
company_name: "Totaligent, Inc."
filed_at: "2026-02-25T23:59:59+00:00"
generated_at: "2026-05-16T00:34:49.843305+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Totaligent signs binding LOI for JV with GloMed and call option to acquire GloMed for $3M cash + 15% equity

## Summary
- GloMed has ~$10M annual revenue and ~$1M free cash flow; distributes biologics/devices in APAC via 20+ KOLs.
- JV will combine Aetherium Medical platform with GloMed's infrastructure; no upfront cash; incremental revenue shared.
- Call option to buy 100% of GloMed within 1 year for $3M cash plus 15% of Totaligent's fully diluted common stock.
- Target JV closing March 22, 2026; subject to due diligence, definitive agreements, and PCAOB audit for option exercise.
- Exclusivity through April 22, 2026; board seats: DeFeudis, Heath, Klarich; Totaligent appoints 3 seats for strategic control.

## SEC filing metadata
- accession: 0001477932-26-001016
- form_type: 8-K
- ticker: TGNT
- cik: 0000846377
- company_name: Totaligent, Inc.
- filed_at: 2026-02-25T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/846377/000147793226001016/0001477932-26-001016-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/846377/000147793226001016/totaligent_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001477932-26-001016
- JSON: https://secwatch.observer/filing/0001477932-26-001016.json
- Plain text: https://secwatch.observer/filing/0001477932-26-001016.txt

## Key facts
- Material Agreements
  Totaligent, Inc. entered into Binding Letter of Intent with GloMed Solutions Limited Liability Company (effective 2026-02-22).
  - Action: entry
  - Counterparty: GloMed Solutions Limited Liability Company
  - Effective: 2026-02-22
  source text: On February 22, 2026, Totaligent, Inc. (the “Company”) entered into a Binding Letter of Intent (the “LOI”) with GloMed Solutions Limited Liability Company (“GloMed”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/846377/000147793226001016/0001477932-26-001016-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.